MBX Biosciences doses first patient in Phase 3 trial of canvuparatide for hypoparathyroidismAug 27Clinical readoutcanvuparatideMBX Biosciences
MBX Biosciences reports Q2 2026 results, canvuparatide Phase 3 recruitingAug 6Clinical readoutcanvuparatideMBX Biosciences
MBX Biosciences registers Phase 3 trial of canvuparatide for hypoparathyroidismJul 13Trial updatecanvuparatideMBX Biosciences
Sign inSign in